Your browser doesn't support javascript.
loading
A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer.
Franco, Yesenia L; Ramakrishnan, Vidya; Vaidya, Tanaya R; Mody, Hardik; Perez, Luis; Ait-Oudhia, Sihem.
Afiliação
  • Franco YL; Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, USA.
  • Ramakrishnan V; Department of Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, NY, USA.
  • Vaidya TR; Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, USA.
  • Mody H; Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, USA.
  • Perez L; Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, USA.
  • Ait-Oudhia S; Merck & Co., Inc, Kenilworth, NJ, USA. sb.manuscript.submission@gmail.com.
J Pharmacokinet Pharmacodyn ; 48(2): 273-293, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33389550

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Inibidores de Proteínas Quinases Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Inibidores de Proteínas Quinases Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article